v3.26.1
Consolidated Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 28, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 35,846 $ 51,238
Accounts receivable, net 120,525 128,303
Inventory 83,187 82,236
Prepaid and other current assets 10,255 11,065
Total current assets 249,813 272,842
Property and equipment, net 21,294 21,899
Goodwill 7,462 7,462
Intangible assets, net 359,659 368,419
Operating lease assets 4,687 5,122
Deferred tax assets 5,522 5,522
Investment and other assets 2,102 2,293
Total assets 650,539 683,559
Current liabilities:    
Accounts payable 24,050 10,928
Accrued liabilities 101,135 130,242
Current portion of long-term debt 18,750 15,000
Other current liabilities 4,160 4,210
Total current liabilities 148,095 160,380
Long-term debt, less current portion 253,326 278,951
Deferred income tax liabilities 568 433
Other long-term liabilities 14,285 15,348
Total liabilities 416,274 455,112
Commitments and contingencies (Note 11)
Stockholders’ Equity    
Additional paid-in capital 522,912 520,851
Accumulated deficit (331,816) (334,929)
Accumulated other comprehensive loss (2,279) (1,900)
Total stockholders’ equity attributable to Bioventus Inc. 188,901 184,105
Noncontrolling interest 45,364 44,342
Total stockholders’ equity 234,265 228,447
Total liabilities and stockholders’ equity 650,539 683,559
Common Class A    
Stockholders’ Equity    
Common stock, value 68 67
Common Class B    
Stockholders’ Equity    
Common stock, value $ 16 $ 16